Novartis reported three clinical trial setbacks this week, including a failed Phase III study for myotonic dystrophy, a cardiovascular drug that missed its primary endpoint, and a suspended CAR-T cell therapy program after three patient deaths. On Tuesday, Novartis announced that its experimental drug for myotonic dystrophy failed to meet its primary endpoint in an advanced clinical trial ^[1]. The drug, del-desiran, did not meet the primary endpoint in the Phase III HARBOR clinical trial for myotonic dystrophy type 1 in placebo-controlled studies ^[4]. Separately, Novartis reported that its pelacarsen drug failed to significantly improve cardiovascular outcomes in a late-stage clinical trial despite reducing lipoprotein(a) levels ^[2]. Novartis also suspended its experimental CAR-T cell therapy program rap-cel, tested for autoimmune indications, after three patients died during clinical trials. Novartis and public authorities froze all clinical testing pending safety reviews ^[3].